PIRS — Pieris Pharmaceuticals Income Statement
0.000.00%
Last trade - 00:00
- $9.57m
- -$9.51m
- $42.81m
- 28
- 88
- 20
- 42
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 46.3 | 29.3 | 31.4 | 25.9 | 42.8 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 73.4 | 63.2 | 79.6 | 61.2 | 72.6 |
Operating Profit | -27.2 | -33.9 | -48.1 | -35.3 | -29.8 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -25.5 | -37.1 | -45.7 | -33.3 | -24.5 |
Provision for Income Taxes | |||||
Net Income After Taxes | -25.5 | -37.2 | -45.7 | -33.3 | -24.5 |
Net Income Before Extraordinary Items | |||||
Net Income | -25.5 | -37.2 | -45.7 | -33.3 | -24.5 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -28.3 | -37.2 | -45.7 | -33.3 | -24.5 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -44.7 | -54.7 | -61.3 | -44.7 | -2.76 |